Health News Round-Up: FDA Approvals and Market Movements
The latest health news includes Church & Dwight adjusting forecasts due to cautious consumer spending, FDA's approval of Adaptimmune's new cancer therapy, and the availability updates of Eli Lilly's weight-loss and diabetes drugs. The updates reflect significant trends and developments in the health sector.
![Health News Round-Up: FDA Approvals and Market Movements](https://devdiscourse.blob.core.windows.net/aiimagegallery/02_06_2024_20_56_14_1535698.png)
The latest developments in health news reveal significant shifts and approvals that could impact the industry.
Church & Dwight has adjusted its full-year sales and profit forecasts downward due to consumer caution on spending for its premium household and personal care products, leading to a 4.3% drop in premarket shares for the Trojan condom maker.
The US FDA has given the green light to Adaptimmune's groundbreaking treatment, Tecelra, for a rare cancer affecting soft tissues, specifically synovial sarcoma. This approval offers new hope for patients who have undergone prior chemotherapy.
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are now fully available, according to the FDA's latest update, though the drugs remain on the shortage list.
(With inputs from agencies.)